Taken together, these results suggested that CRC pretreated with MRS2578 induces cell killing and abrogates LRP16-mediated NF-κB activation in response to etoposide, leading to conversion of LRP16 from a survival into a killer molecule. The gene discussed is NFKB1; the disease is colorectal carcinoma.